Form 4: Altimmune Director Vipin Garg's Stock Transactions

Altimmune Director Vipin Garg reported recent acquisitions and dispositions of company common stock, including RSU vesting and ESPP purchases.

Summary

• Director Vipin K. Garg reported changes in beneficial ownership of Altimmune, Inc. common stock.
• On January 30, 2026, 26,775 shares were acquired through the vesting of Restricted Stock Units (RSUs) at a price of $0.
• On the same date, 11,632 shares were disposed of at $5.60 per share to cover tax obligations related to the RSU vesting.
• On January 31, 2026, 6,926 shares were purchased at $3.07 per share through the company's 2019 Employee Stock Purchase Plan (ESPP).
• The ESPP purchase price was 85% of the closing price on August 1, 2025.
• Following these transactions, Vipin K. Garg directly beneficially owns 424,519 shares of Altimmune common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as the director's beneficial ownership increased through RSU vesting and ESPP participation, indicating continued alignment with shareholder interests, despite a routine tax-related share disposition.

Positives

• Director Vipin K. Garg acquired 26,775 shares through RSU vesting, indicating continued long-term incentive alignment.
• An additional 6,926 shares were purchased through the Employee Stock Purchase Plan (ESPP) at a discounted price of $3.07, demonstrating ongoing insider investment.

Negatives

• 11,632 shares were disposed of to cover tax liabilities, which is a common practice but represents a reduction in direct holdings.

Future Outlook

N/A

Industry Context

StockSavvy.ai notes that insider transactions, such as those reported in a Form 4, provide insights into management's confidence in the company. While RSU vesting and ESPP purchases are often part of compensation plans, the net effect on beneficial ownership can signal management's long-term view, particularly in the biotechnology sector where R&D milestones and regulatory approvals heavily influence stock performance.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures for insider transactions across all industries.
• The specific details of RSU vesting schedules and ESPP discounts are company-specific and not directly comparable to global benchmarks without further context on Altimmune's compensation structure relative to peers like Viking Therapeutics or Madrigal Pharmaceuticals.
• However, participation in ESPP at a discount is a common incentive mechanism.

Stakeholder Impact

• Shareholders: Increased insider ownership (net) can be seen as a positive signal of confidence.
• Employees: The ESPP participation highlights the availability of employee stock purchase programs.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to compensation (RSU vesting and ESPP purchase) and tax obligations. While the director's beneficial ownership increased slightly, these are not open-market discretionary purchases or sales that would significantly alter the investment thesis. Investors should consider these transactions as part of a broader analysis of Altimmune's fundamentals and market position rather than a standalone signal for a strong buy or sell.

Keywords

Altimmune, ALT, Vipin Garg, Form 4, Insider Trading, Stock Ownership, Restricted Stock Units, ESPP, Director, Beneficial Ownership